Summer Solstice 2025: The Exact Time For Every U.S. State
The 2025 solstice — the longest day of the year in the Northern Hemisphere and the shortest in the Southern Hemisphere — will occur at 02:42 UTC on Saturday, June 21. However, in North America, it happens the previous day.
People watch the sun rise, as they take part in the Summer Solstice at Stonehenge in Wiltshire, ... More Friday, June 21, 2024. (Andrew Matthews/PA Wire/PA via AP)
June's solstice marks the longest day of the year and the beginning of astronomical summer in the Northern Hemisphere. It's not only the longest day but also the point when daylight begins to shorten.
The solstice occurs at a specific global time (02:42 UTC on June 21), so its local time varies across U.S. time zones. The 2025 summer solstice occurs at 10:42 p.m. EDT, 9:42 p.m. CDT, 8:42 p.m. MDT, 7:42 p.m. PDT, 6:42 p.m. AKDT and 4:42 p.m. HST on Friday, June 20.
At that precise moment, the sun will be directly overhead at the Tropic of Cancer at noon somewhere on Earth. It's the northernmost point of the sun at noon.
Solstice is from the Latin solstitium, sol meaning sun and stit being stationary. That's because, as a consequence of the sun reaching its highest in the sky in the Northern Hemisphere, its rise and set points are at their extreme northeast and northwest, respectively. To the observer, the sun appears to rise farther northeast until June's solstice, when it appears to stand still for a few mornings before rising farther east and south.
Although Stonehenge is traditionally associated with the solstice (it's aligned with the rising sun on the solstice), there are other ancient monuments with a solstice link. Egypt's Nabta Playa stone circle, the oldest known astronomical site, tracks the solstice, with no shadows cast by its stones at noon on the date of the solstice. According to Astronomy magazine, Nabta Playa was constructed by a cattle-worshiping cult of nomadic people to mark the summer solstice and the arrival of the monsoons. At 7,000 years old, it's older than Stonehenge.
The 2025 solstice will occur at 02:42 UTC on Saturday, June 21, 2025.
The Tropic of Cancer is a line 23.4 degrees north of the Earth's equator through The Bahamas, Mexico, Egypt, Libya, Niger, Algeria, Mauritania, Mali, Chad, Saudi Arabia, United Arab Emirates, Oman, India, Myanmar, China and Taiwan. It reflects the tilt of the Earth's axis, which explains why the planet has solstices, equinoxes and seasons.
The beginning of astronomical seasons is marked by solstices and equinoxes (equinox means equal night when there are 12 hours of daylight and 12 hours of darkness). The spring or vernal equinox occurs between March 19-21, the June solstice June 20 and 22, the September equinox September 21-24 and the December solstice is December 20-23, according to Timeanddate.com. In 2025, they occur on March 20, June 20, Sept. 22 and Dec. 21, respectively.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
43 minutes ago
- Medscape
Fast Five Quiz: Cancer Diagnostics and Precision Medicine
Over the past decade, precision medicine has transformed cancer diagnostics and treatment by tailoring therapy to a patient's tumor biology based on molecular alterations rather than histologic subtypes or origins. Precision oncology often relies on molecular profiling through next-generation sequencing (NGS) to identify genomic events that can guide management. Techniques like targeted panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) provide different analysis levels, chosen based on tumor type, tissue, and therapy relevance. How much do you know about cancer diagnostics and precision medicine? Test your knowledge with this quick quiz. WGS is an NGS method that analyzes the entire DNA sequence of an organism, including both coding and noncoding regions. WGS offers broad genomic coverage, detecting structural variants, intergenic mutations, and copy number changes often missed by targeted methods. Clinically, it has been useful in identifying ERBB2 ( HER2 ) amplifications in breast cancer or complex epidermal growth factor receptor ( EGFR ) alterations in lung cancer that might not be captured by smaller panels, helping guide targeted therapy. However, its lower sequencing depth (30-60×) typically limits the detection of low-frequency variants in heterogeneous tumors, such as a subclonal TP53 mutation affecting a small subset of cells and potentially impacting treatment response, which WGS may miss due to its lower depth. WES focuses only on the protein-coding regions, offering greater depth than WGS but limited breadth; however, it misses important regulatory and noncoding mutations. For example, TERT promoter mutations in glioblastoma are clinically relevant but lie outside the exome and would be missed by WES. Targeted panels are NGS tests that focus on specific disease-related genes and, until recently, were the predominant method used for comprehensive genomic profiling in clinical settings. They offer high depth for detecting low-frequency, actionable mutations but have limited coverage and might miss rare alterations outside the selected genes. Sanger sequencing is a method that reads DNA by generating fragments of varying lengths using chain-terminating nucleotides. It is accurate for small regions but has low throughput and cannot detect low-frequency mutations, making it unsuitable for large-scale cancer genomics. Unlike WGS, which surveys the entire genome, Sanger covers only targeted regions, so it does not offer broad genomic coverage and is therefore not the correct answer. Learn more about molecular profiling in oncology diagnostics. TS panels analyze specific genes relevant to oncology, and by focusing on a smaller subset of the genome (a few dozen to a few hundred genes), these panels require fewer sequencing data, resulting in faster turnaround times and simplified data interpretation compared with WGS or WES. This targeted approach enhances sensitivity for detecting clinically actionable somatic mutations, especially in small or heterogeneous tumor samples. For example, targeted NGS panels in non-small cell lung cancer (NSCLC) can rapidly detect EGFR mutations, ALK rearrangements, and other actionable alterations, allowing oncologists to initiate targeted therapies based on the mutation profile promptly. TS also demands less data storage and computational processing compared with WGS or WES, resulting in faster turnaround times and lower costs. These attributes make TS especially well-suited for clinical settings where accuracy, speed, and cost-effectiveness are paramount Learn more about clinical practice guidelines in the use of precision medicine in oncology. Tissue is generally preferred for initial genomic profiling because it contains a higher concentration of tumor DNA, allowing for more accurate detection of somatic mutations. This is especially important in early-stage cancers or tumors that do not shed much DNA into the bloodstream to be detectable by liquid biopsy. The tissue also allows for additional analyses like immunohistochemistry for PD-L1 or assessment of tumor histology to guide therapy. Further, immunohistochemistry plays an important role in precision medicine by identifying protein biomarkers to help determine the use of immune checkpoint inhibitors in NSCLC, triple-negative breast cancer, and urothelial carcinoma. Blood-based tests (ie, liquid biopsies) generally yield lower tumor DNA and do not inherently offer deeper sequencing but are generally more cost-effective than tissue biopsies. Regulatory agencies currently accept blood-based tests (eg, FDA-approved liquid biopsies), but they are typically used when tissue is unavailable or there is insufficient tissue. Learn more about tissue-based profiling Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), has emerged as a valuable tool for monitoring MRD after treatment. By detecting small amounts of tumor-derived genetic material in the blood, liquid biopsy enables early identification of molecular relapse, often before clinical or radiographic evidence of recurrence is apparent. This makes it particularly useful in post-treatment surveillance of cancers such as colorectal, breast, and NSCLC. Diagnosing lymphomas typically requires tissue biopsy to assess architectural patterns and immunophenotyping; it is also commonly regarded as the standard for diagnosis. PD-L1 expression is a protein-based biomarker typically measured by immunohistochemistry on tissue samples, not usually through ctDNA. However, researchers have stated, 'ctDNA response is a potential biomarker for predicting the efficacy and prognosis of first-line PD-1 inhibitor therapy combined with chemotherapy' in patients with advanced gastric cancer. ctDNA also has been shown to predict responses in patients using PD-1/PD-L1 immune checkpoint inhibitors. Tumor staging usually relies on imaging modalities and pathologic evaluation rather than ctDNA analysis alone. Learn more about clinical practice guidelines in the use of precision medicine in oncology. A high TMB is considered useful because it is associated with abnormal proteins that make the tumor more recognizable to the immune system. TMB is measured using NGS by counting the number of somatic, nonsynonymous mutations per megabase of DNA; it is typically assessed using WES or large targeted panels. A TMB of 10 or more mutations per megabase is considered 'high,' based on data from the KEYNOTE-158 trial. This led to the FDA approval of an immune checkpoint inhibitor for TMB-high solid tumors, for example. High TMB is not usually linked to fewer side effects; side effect profiles tend to depend on the therapy, not mutation count. Low TMB has been shown to lead to fewer neoantigens and typically less immune visibility. Typically, TMB directly measures the number of mutations, not PD-L1 protein expression. Learn more about immunotherapy diagnostics.
Yahoo
2 hours ago
- Yahoo
The summer solstice is today. Here's what to expect on the 1st day of summer.
Today will be the longest day of 2025 in the Northern Hemisphere, kicking off the coveted summer season. The 2025 summer solstice is expected to officially start on June 20 at 10:42 p.m. ET, according to the Farmers Almanac. It's at that time that the sun will be at its northernmost point for the Northern Hemisphere. Astronomers recognize the summer solstice as the first day of summer, although it's not necessarily considered the 'official' start of summer. 'The June solstice marks a precise moment in Earth's orbit — a consistent astronomical signpost that humans have observed for millennia,' NASA says. 'Ancient structures from Stonehenge to Chichén Itzá were built, in part, to align with the solstices, demonstrating how important these celestial events were to many cultures.' Thousands of visitors are expected to flock to areas throughout the Northern Hemisphere to celebrate through rituals: from Stonehenge in Wiltshire, England, to midsummer festivals across Sweden, Denmark, Norway and Finland. Here's what to know about the summer solstice. 'Solstice' comes from the Latin words 'sol' (meaning sun) and 'sistere' (to stand still), according to the Farmers' Almanac, and it describes the Earth's angle between the sun's rays. The summer solstice is the longest day of the year for the Northern Hemisphere because this is when the Earth's north pole is tilted toward the sun at its most extreme angle. Solstices only happen twice a year, the second time being when the Northern Hemisphere experiences its winter solstice in December, which is when the Earth's south pole is tilted toward the sun at its most extreme angle. On Friday, the Northern Hemisphere will experience its official first days of summer and longest hours of daylight for the entire year. Areas around the equator will experience sunlight for about 12 hours straight, according to while more mid-northern areas will get 15 hours. Since the Earth's north pole is tilted so close to the sun, areas north of the Arctic Circle will experience sunlight for 24 hours. The summer solstice can happen anytime between June 20 and June 22, depending on the time zone. While we measure years in 365 days — or 366 days for a leap year — astronomically speaking, Earth actually takes 365.242199 days to orbit the sun. This affects what time and day the summer solstice will actually occur. In a lot of Northern Hemisphere locations, areas will experience earlier sunrises before the official solstice day, and some later sunsets happen days after it, according to Time and Date, a global platform that analyzes time zone and astronomy data. The solstice day never being official or aligned every year is common since the sun's solar time is never precise or consistent with how our clocks and calendars operate. Astronomers have studied the sun's timing compared to how we measure time with clocks and calendars, and refer to the difference as 'the equation of time.' Solstices and equinoxes seem to kick off a change in the seasons on Earth, but there are significant differences between the two experiences. Just compare the 2025 spring equinox, which happened on March 20, to what is expected to happen during the upcoming summer solstice on Friday. Summer and winter solstices are when the Earth's tilt toward the sun is at its maximum, so the summer solstice is when the Northern Hemisphere experiences its longest day of sunlight and shortest night, and the winter solstice is when the Northern Hemisphere experiences its shortest day of sunlight and longest night. During an equinox, the Earth is not tilted anywhere directly, and the sun falls right over the equator, which means that there will be 'nearly' equal amounts of daylight and darkness at all latitudes, according to the National Weather Service.
Yahoo
2 hours ago
- Yahoo
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States
Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes SAN DIEGO, June 20, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their AID systems to fit their unique healthcare and lifestyle needs," said Dr. Jordan Pinsker, chief medical officer of Tandem Diabetes Care. "The American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott's latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology." The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim mobile app, providing users with multiple, convenient ways to access their current glucose trend. The t:slim X2 insulin pump is powered by Control-IQ+ technology, the latest generation of Tandem's advanced hybrid closed-loop algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It's the only system with the unique AutoBolus™ feature that calculates and delivers a correction bolus to help with missed meal boluses.* Control-IQ+ is easy to start, use, and personalize, and this latest integration works with the FreeStyle Libre 3 Plus sensor and extends its benefits to even more people with diabetes. "This is an exciting first step in our strategy to connect Tandem's portfolio of insulin pumps to Abbott's FreeStyle Libre 3 Plus sensors worldwide," said John Sheridan, president and chief executive officer of Tandem Diabetes Care. "We look forward to expanding access to our t:slim X2 users outside of the U.S. beginning later this year." When available, Tandem will email eligible users in the U.S. with more information.† About Tandem Diabetes CareTandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow Tandem Diabetes Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and # Tandem Diabetes Care on Facebook at Tandem Diabetes Care on LinkedIn at Forward Looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our ability to provide the software update for current t:slim X2 pump users and the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These statements are subject to numerous risks and uncertainties, including our ability to sustain commercial scale manufacturing of the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software, our ability to operate and maintain a system to facilitate online training for existing t:slim X2 pump customers upgrading their existing devices, and the risk that we may encounter other challenges that may delay the availability of the software update for current t:slim X2 pump users or the t:slim X2 pumps pre-loaded with Freestyle Libre 3 Plus sensor integration software. These and other risks are identified and described in greater detail under the "Risk Factors" heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors. Important Safety Information – FreeStyle Libre SystemsProduct for prescription only; for Important Safety Information, please visit Important Safety Information – Tandem Diabetes CareRX ONLY. The t:slim X2 pump with interoperable technology (the pump) and Control-IQ+ technology (Control-IQ+) are intended for single patient use. The pump and Control-IQ+ are indicated for use with NovoLog or Humalog U-100 insulin. t:slim X2 insulin pump: The pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater. Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of Type 1 diabetes mellitus in persons 2 years of age and greater and of Type 2 diabetes mellitus in persons 18 years of age and greater. WARNING: Control-IQ+ should not be used in anyone under the age of 2 years old with Type 1 diabetes or under the age of 18 years old with Type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely. Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit for additional important safety information. © 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, t:slim X2, t:slim, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners. * If glucose values are predicted to be above 180 mg/dL (or 10.0 mmol/L), Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 110 mg/dL (or 6.1 mmol/L) and delivers 60% of that value. † Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion. View source version on Contacts Media Contact: 858-366-6900media@ Investor Contact: 858-366-6900IR@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
